<DOC>
	<DOCNO>NCT00005070</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irofulven treat patient stage IVB recurrent cervical cancer .</brief_summary>
	<brief_title>Irofulven Treating Patients With Stage IVB Recurrent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy 6-hydroxymethylacylfulvene patient stage IVB recurrent cervical carcinoma . II . Determine safety drug patient population . OUTLINE : Patients receive 6-hydroxymethylacylfulvene IV 5 minute daily 5 consecutive day . Treatment continue every 28 day absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 6-19 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary metastatic ( stage IVB ) recurrent cervical carcinoma amenable curative therapy Squamous Adenocarcinoma Adenosquamous Bidimensionally measurable disease No active brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal ALT/AST great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN ( 1.95 mg/dL MSKCC ) OR Creatinine clearance least 50 mL/min Cardiovascular : No New York Heart Association class III IV congestive heart failure No ECG evidence acute ischemia No significant conduction abnormality ( e.g. , bifascicular block , 2nd 3rd degree AV block ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year deem low risk recurrence No concurrent clinical circumstance would compromise safety integrity trial PRIOR CONCURRENT THERAPY : Prior multimodality therapy diagnosis allow ( i.e. , concurrent chemotherapy radiotherapy , neoadjuvant chemotherapy follow surgery and/or radiotherapy , adjuvant chemotherapy and/or radiotherapy follow surgery , adjuvant chemotherapy follow radiotherapy ) Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic recurrent disease Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior major surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>